Parkinson's disease treatment may cause impulse-control disorder via dopamine D3 receptors.
Identifieur interne : 000601 ( Main/Exploration ); précédent : 000600; suivant : 000602Parkinson's disease treatment may cause impulse-control disorder via dopamine D3 receptors.
Auteurs : Philip Seeman [Canada]Source :
- Synapse (New York, N.Y.) [ 1098-2396 ] ; 2015.
English descriptors
- KwdEn :
- MESH :
- chemical , adverse effects : Antiparkinson Agents, Dopamine Agonists.
- drug therapy : Parkinson Disease.
- etiology : Disruptive, Impulse Control, and Conduct Disorders.
- chemical , metabolism : Receptors, Dopamine D3.
- Animals, Humans.
Abstract
In treating Parkinson's disease with dopaminergic agonists, such as pramipexole, ropinirole, pergolide, rotigotine, apomorphine, or bromocriptine, it has been observed that a significant number of patients develop impulse-control disorders, such as compulsive shopping, pathological gambling, or hypersexuality. Because the dopamine agonists have high affinities for the dopamine D2 and D3 receptors, the drug dissociation constants of these drugs at the functional high-affinity states of these receptors, namely D2High and D3High, were compared. The data show that, compared to the other dopamine agonist drugs, pramipexole has a relatively high selectivity for the dopamine D3 receptor, as compared to D2, suggesting that the D3 receptor may be a primary target for pramipexole. There is a trend showing that the proportion of impulse-control disorders is related to the selectivity for D3 receptors over D2 receptors, with pramipexole having the highest association with, or frequency of, impulse-control disorders. While the number of studies are limited, the proportion of patients with impulse-control disorder in Parkinson patients treated with an add-on agonist were 32% for pramipexole, 25% for ropinirole, 16% for pergolide, 22% for rotigotine, 10% for apomorphine, and 6.8% for bromocriptine. Clinically, temporary replacement of pramipexole by bromocriptine may provide relief or reversal of the impulsive behavior associated with selective D3 stimulation by either pramipexole or ropinirole, while maintaining D2 stimulation needed for the anti-Parkinson action.
DOI: 10.1002/syn.21805
PubMed: 25645960
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000533
- to stream PubMed, to step Curation: 000533
- to stream PubMed, to step Checkpoint: 000533
- to stream Ncbi, to step Merge: 001A54
- to stream Ncbi, to step Curation: 001A54
- to stream Ncbi, to step Checkpoint: 001A54
- to stream Main, to step Merge: 000602
- to stream Main, to step Curation: 000601
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Parkinson's disease treatment may cause impulse-control disorder via dopamine D3 receptors.</title><author><name sortKey="Seeman, Philip" sort="Seeman, Philip" uniqKey="Seeman P" first="Philip" last="Seeman">Philip Seeman</name><affiliation wicri:level="4"><nlm:affiliation>Departments of Pharmacology and Psychiatry, Faculty of Medicine, University of Toronto, 260 Heath Street West, Unit 605, Toronto, Ontario, M5P 3L6, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Departments of Pharmacology and Psychiatry, Faculty of Medicine, University of Toronto, 260 Heath Street West, Unit 605, Toronto, Ontario, M5P 3L6</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:25645960</idno><idno type="pmid">25645960</idno><idno type="doi">10.1002/syn.21805</idno><idno type="wicri:Area/PubMed/Corpus">000533</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000533</idno><idno type="wicri:Area/PubMed/Curation">000533</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000533</idno><idno type="wicri:Area/PubMed/Checkpoint">000533</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000533</idno><idno type="wicri:Area/Ncbi/Merge">001A54</idno><idno type="wicri:Area/Ncbi/Curation">001A54</idno><idno type="wicri:Area/Ncbi/Checkpoint">001A54</idno><idno type="wicri:Area/Main/Merge">000602</idno><idno type="wicri:Area/Main/Curation">000601</idno><idno type="wicri:Area/Main/Exploration">000601</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Parkinson's disease treatment may cause impulse-control disorder via dopamine D3 receptors.</title><author><name sortKey="Seeman, Philip" sort="Seeman, Philip" uniqKey="Seeman P" first="Philip" last="Seeman">Philip Seeman</name><affiliation wicri:level="4"><nlm:affiliation>Departments of Pharmacology and Psychiatry, Faculty of Medicine, University of Toronto, 260 Heath Street West, Unit 605, Toronto, Ontario, M5P 3L6, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Departments of Pharmacology and Psychiatry, Faculty of Medicine, University of Toronto, 260 Heath Street West, Unit 605, Toronto, Ontario, M5P 3L6</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation></author></analytic><series><title level="j">Synapse (New York, N.Y.)</title><idno type="eISSN">1098-2396</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antiparkinson Agents (adverse effects)</term><term>Disruptive, Impulse Control, and Conduct Disorders (etiology)</term><term>Dopamine Agonists (adverse effects)</term><term>Humans</term><term>Parkinson Disease (drug therapy)</term><term>Receptors, Dopamine D3 (metabolism)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term><term>Dopamine Agonists</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Disruptive, Impulse Control, and Conduct Disorders</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Receptors, Dopamine D3</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Humans</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In treating Parkinson's disease with dopaminergic agonists, such as pramipexole, ropinirole, pergolide, rotigotine, apomorphine, or bromocriptine, it has been observed that a significant number of patients develop impulse-control disorders, such as compulsive shopping, pathological gambling, or hypersexuality. Because the dopamine agonists have high affinities for the dopamine D2 and D3 receptors, the drug dissociation constants of these drugs at the functional high-affinity states of these receptors, namely D2High and D3High, were compared. The data show that, compared to the other dopamine agonist drugs, pramipexole has a relatively high selectivity for the dopamine D3 receptor, as compared to D2, suggesting that the D3 receptor may be a primary target for pramipexole. There is a trend showing that the proportion of impulse-control disorders is related to the selectivity for D3 receptors over D2 receptors, with pramipexole having the highest association with, or frequency of, impulse-control disorders. While the number of studies are limited, the proportion of patients with impulse-control disorder in Parkinson patients treated with an add-on agonist were 32% for pramipexole, 25% for ropinirole, 16% for pergolide, 22% for rotigotine, 10% for apomorphine, and 6.8% for bromocriptine. Clinically, temporary replacement of pramipexole by bromocriptine may provide relief or reversal of the impulsive behavior associated with selective D3 stimulation by either pramipexole or ropinirole, while maintaining D2 stimulation needed for the anti-Parkinson action.</div></front></TEI><affiliations><list><country><li>Canada</li></country><region><li>Ontario</li></region><settlement><li>Toronto</li></settlement><orgName><li>Université de Toronto</li></orgName></list><tree><country name="Canada"><region name="Ontario"><name sortKey="Seeman, Philip" sort="Seeman, Philip" uniqKey="Seeman P" first="Philip" last="Seeman">Philip Seeman</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000601 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000601 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:25645960
|texte= Parkinson's disease treatment may cause impulse-control disorder via dopamine D3 receptors.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:25645960" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |